Oligonucleotide Therapeutics Society

A Potent ASO Shows Encouraging Results in A Single-Patient Pilot Study for ALS

February 9th, 2022|Categories: Perspectives on Current Science|

Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease in which motor neurons die. Since the motor neurons that die control voluntary muscles, the disease causes great difficulty for those who must live with it. They will experience loss of motor control of the [...]

A Perspective From Industry – A Conversation With Richard S. Geary, Ph.D. Executive Vice President, Chief Development Officer at Ionis Pharmaceuticals

February 3rd, 2022|Categories: Recent Webinar|

Speaker: Richard S. Geary, Ph.D. Date: February 10, 2022 Time: 11-12 EST Description: The OTS Webinar series is pleased to feature Dr. Richard Geary, the current President Elect, and the Executive Vice President, Chief Development Officer at Ionis Pharmaceuticals. For part of the webinar [...]

Clinical Trials Begin for Ultra-Rare Treatment of Alexander Disease

January 1st, 2022|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

It is always exciting to observe phenomenal results in the treatment of a disease in animal studies, and even more so to see them move into clinical trials. ASOs have proven to be efficient at providing deep reductions in disease causing proteins, and a [...]

Looking back… Looking forward

December 24th, 2021|Categories: Blog|

This will be my last contribution that I write as President of our Society. On January 1st, 2022, I will become ‘Immediate Past-President’. David Corey (University of Texas, Southwestern) will take over as President and Richard Geary (Ionis Pharmaceuticals) will become the Society’s next [...]

Go to Top